Revvity announced on February 5, 2026 that it will debut three new discovery platforms at the SLAS2026 conference in Boston, which runs from February 7‑11. The company introduced the Opera Phenix OptIQ high‑content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, all designed to accelerate high‑throughput drug‑discovery workflows.
The Opera Phenix OptIQ raises peak camera quantum efficiency from 60 % to 95 % and incorporates Phenologic.AI image‑analysis software with new classification capabilities, enabling faster and more accurate phenotypic screening. The EnVision Nexus One offers multimode detection—fluorescence, absorbance, luminescence, and time‑resolved fluorescence—in a single instrument, while the AssayMate provides a compact, 8‑channel benchtop liquid handler that streamlines sample preparation and assay execution.
Revvity’s Q4 2025 earnings, released on February 2, 2026, showed an adjusted EPS of $1.70 versus consensus estimates of $1.55–$1.63, a beat of $0.07–$0.15. Revenue for the quarter reached $772.06 million, slightly above the $759.81–$771.9 million consensus. The company also issued 2026 guidance of $2.96 billion to $2.99 billion in revenue and $5.35 to $5.45 in adjusted EPS, both above analyst expectations.
CEO Prahlad Singh highlighted that the company’s portfolio transformation has positioned it to capitalize on improving end‑market conditions. He noted that the new platforms “strengthen our end‑to‑end solution set and reinforce our commitment to delivering differentiated results in the coming years.” The launch aligns with Revvity’s strategy to integrate automation, trusted assay technologies, and AI‑driven imaging across the drug‑discovery pipeline.
The market reacted positively to the earnings beat and forward guidance, with analysts citing Revvity’s disciplined cost management and strong demand in core segments as key drivers. The new platforms are expected to enhance customer stickiness and expand Revvity’s competitive edge against other life‑sciences solution providers.
Looking ahead, the addition of the Opera Phenix OptIQ, EnVision Nexus One, and AssayMate positions Revvity to capture growing demand for integrated, AI‑enabled discovery tools. The company’s robust financial footing and strategic focus on high‑impact platforms suggest continued momentum in both revenue growth and margin expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.